头孢他啶-阿维巴坦在重症儿童大容量连续静脉-静脉血液渗滤中的体内/体外比较研究

IF 2.3 4区医学 Q2 PHARMACOLOGY & PHARMACY

Pharmacology Research & Perspectives Pub Date : 2025-08-01 DOI:10.1002/prp2.70139

Michael Thy, Alexandre Debs, Gabrielle Lui, Leo Froelicher-Bournaud, Jean-Marc Tréluyer, Mehdi Oualha

{"title":"头孢他啶-阿维巴坦在重症儿童大容量连续静脉-静脉血液渗滤中的体内/体外比较研究","authors":"Michael Thy, Alexandre Debs, Gabrielle Lui, Leo Froelicher-Bournaud, Jean-Marc Tréluyer, Mehdi Oualha","doi":"10.1002/prp2.70139","DOIUrl":null,"url":null,"abstract":"Ceftazidime-avibactam is a novel cephalosporin/beta-lactamase inhibitor combination developed to address increasing antimicrobial resistance. This report presents a comparative study of the pharmacokinetics of ceftazidime and avibactam, utilizing in vitro data derived from two experiments with continuous venovenous hemodiafiltration (CVVHDF) simulation and a comparison with a previously published in vivo case report. The results highlight the importance of therapeutic drug monitoring and the need for higher dosing or continuous infusion of ceftazidime-avibactam in critically ill children under crontinuous renal replacement therapy (CRRT).","PeriodicalId":19948,"journal":{"name":"Pharmacology Research & Perspectives","volume":"13 4","pages":"e70139"},"PeriodicalIF":2.3000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12271520/pdf/","citationCount":"0","resultStr":"{\"title\":\"Ceftazidime-Avibactam Pharmacokinetic Comparative In Vivo/In Vitro Study in a Critically Ill Children Under High-Volume Continuous Venovenous Hemodiafiltration.\",\"authors\":\"Michael Thy, Alexandre Debs, Gabrielle Lui, Leo Froelicher-Bournaud, Jean-Marc Tréluyer, Mehdi Oualha\",\"doi\":\"10.1002/prp2.70139\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Ceftazidime-avibactam is a novel cephalosporin/beta-lactamase inhibitor combination developed to address increasing antimicrobial resistance. This report presents a comparative study of the pharmacokinetics of ceftazidime and avibactam, utilizing in vitro data derived from two experiments with continuous venovenous hemodiafiltration (CVVHDF) simulation and a comparison with a previously published in vivo case report. The results highlight the importance of therapeutic drug monitoring and the need for higher dosing or continuous infusion of ceftazidime-avibactam in critically ill children under crontinuous renal replacement therapy (CRRT).\",\"PeriodicalId\":19948,\"journal\":{\"name\":\"Pharmacology Research & Perspectives\",\"volume\":\"13 4\",\"pages\":\"e70139\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12271520/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacology Research & Perspectives\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/prp2.70139\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacology Research & Perspectives","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/prp2.70139","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

头孢他啶-阿维巴坦是一种新型头孢菌素/ β -内酰胺酶抑制剂联合开发，以解决日益增加的抗菌素耐药性。本报告对头孢他啶和阿维巴坦的药代动力学进行了比较研究，利用了两个连续静脉静脉血液渗滤（CVVHDF）模拟实验得出的体外数据，并与先前发表的体内病例报告进行了比较。这些结果强调了治疗药物监测的重要性，以及在接受持续肾替代治疗（CRRT）的危重儿童中需要更高剂量或持续输注头孢他啶-阿维巴坦。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Ceftazidime-Avibactam Pharmacokinetic Comparative In Vivo/In Vitro Study in a Critically Ill Children Under High-Volume Continuous Venovenous Hemodiafiltration.

查看原文本刊更多论文

Ceftazidime-Avibactam Pharmacokinetic Comparative In Vivo/In Vitro Study in a Critically Ill Children Under High-Volume Continuous Venovenous Hemodiafiltration.

Ceftazidime-avibactam is a novel cephalosporin/beta-lactamase inhibitor combination developed to address increasing antimicrobial resistance. This report presents a comparative study of the pharmacokinetics of ceftazidime and avibactam, utilizing in vitro data derived from two experiments with continuous venovenous hemodiafiltration (CVVHDF) simulation and a comparison with a previously published in vivo case report. The results highlight the importance of therapeutic drug monitoring and the need for higher dosing or continuous infusion of ceftazidime-avibactam in critically ill children under crontinuous renal replacement therapy (CRRT).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pharmacology Research & Perspectives Pharmacology, Toxicology and Pharmaceutics-General Pharmacology, Toxicology and Pharmaceutics

CiteScore

5.30

自引率

3.80%

发文量

120

审稿时长

20 weeks

期刊介绍： PR&P is jointly published by the American Society for Pharmacology and Experimental Therapeutics (ASPET), the British Pharmacological Society (BPS), and Wiley. PR&P is a bi-monthly open access journal that publishes a range of article types, including: target validation (preclinical papers that show a hypothesis is incorrect or papers on drugs that have failed in early clinical development); drug discovery reviews (strategy, hypotheses, and data resulting in a successful therapeutic drug); frontiers in translational medicine (drug and target validation for an unmet therapeutic need); pharmacological hypotheses (reviews that are oriented to inform a novel hypothesis); and replication studies (work that refutes key findings [failed replication] and work that validates key findings). PR&P publishes papers submitted directly to the journal and those referred from the journals of ASPET and the BPS